Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Alphatec is a medical technology company focused on the design, development, manufacturing, and marketing of products for the surgical treatment of spine disorders, with a specific focus on the aging spine. Operations are conducted primarily through Alphatec Spine and subsidiaries in the U.S., Japan (Alphatec Pacific), and Europe.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 |
|---|---|---|
| Revenues | $25.8 million | $72.9 million |
| Gross Profit | $16.7 million (64.7% margin) | $47.9 million (65.7% margin) |
| Operating Loss | $(4.5) million | $(23.6) million |
| Net Loss | $(4.9) million | $(24.2) million |
| Net Loss Per Share (Basic/Diluted) | $(0.10) | $(0.52) |
| Cash and Cash Equivalents | $10.9 million (as of Sep 30, 2008) | N/A |
| Line of Credit Drawn | $12.8 million | N/A |
| Available Credit | ~$2.0 million | N/A |
Cash Flow (Nine Months Ended Sep 30, 2008):
- Net cash used in operating activities: $(18.2) million
- Net cash used in investing activities: $(7.2) million
- Net cash provided by financing activities: $10.6 million
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 27.1% ($5.5 million) for the three months and 24.2% ($14.2 million) for the nine months compared to the prior year periods. Growth was driven by increased sales of Trestle, Novel, and Zodiac product lines in the U.S. and the acquisition of Japan Ortho Medical.
- Operating Expenses: Total operating expenses increased significantly due to higher R&D spending ($2.1 million increase for the quarter) and a one-time litigation settlement of $11.0 million recorded in the nine-month period of 2008 (vs. none in 2007).
- Profitability: While gross margins improved (64.7% vs. 63.7% for the quarter), the company reported a net loss of $24.2 million for the nine months, compared to $8.9 million in the prior year, primarily due to the litigation settlement and increased R&D/IPR&D costs.
- Liquidity: Cash and cash equivalents decreased from $25.8 million at year-end 2007 to $10.9 million at September 30, 2008. The company increased its line of credit draw to $12.8 million.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- Litigation Settlement: A $11.0 million one-time payment was made in May 2008 to settle patent infringement claims with Biedermann Motech GmbH and DePuy Spine, Inc. This included a license to the 678 Patent and ongoing royalties.
- Deferred Revenue: Approximately $2.9 million of revenue is deferred as of September 30, 2008, related to shipments to a new European distributor and a new U.S. distributor due to extended payment terms or lack of credit history.
- Accounting Change: The estimated useful life of spinal instrumentation was extended from two to four years effective January 1, 2008, reducing depreciation expense by $2.0 million for the nine months ended September 30, 2008.
- Outlook: Management believes current cash, revenues, and credit facilities are sufficient to fund operations through at least September 30, 2009. However, the company expects to continue incurring operating losses as it invests in R&D and sales expansion.
- Risks and Contingencies:
- Legal Proceedings: Ongoing litigation with four surgeons claiming 6% royalties on polyaxial screw sales; trial scheduled for the first half of 2009.
- Future Milestone Payments: Significant future cash and stock payments are contingent on achieving development milestones for licensed technologies (e.g., OsseoFix, OsseoScrew), totaling approximately $5.7 million in potential cash obligations.
- Market Risk: Exposure to foreign currency fluctuations (primarily Japanese Yen) and commodity price changes (titanium, stainless steel).
Investor Verification Checklist
- Litigation Exposure: Verify the status and potential financial impact of the pending lawsuit regarding surgeon royalties on polyaxial screws.
- Deferred Revenue Recognition: Monitor the collection of the $2.9 million in deferred revenue from new distributors to ensure it converts to recognized revenue as expected.
- Liquidity Position: Assess the company's ability to meet future milestone payments (approx. $5.7 million) and operating needs given the reduced cash balance and reliance on the line of credit.
- R&D Milestones: Track the progress of key licensed technologies (OsseoFix, OsseoScrew, Expandable VBR) to determine if future milestone payments will be triggered.
- Inventory Valuation: Review the adequacy of the $11.8 million reserve for excess and obsolete inventory, particularly given the introduction of new products and changes in demand.